Iniciar sesión Regístrese gratis

Edesa Biotech Retorno sobre activos

¿Qué es el Retorno sobre activos de Edesa Biotech?

El Retorno sobre activos de Edesa Biotech, Inc. es -97.50%

¿Cuál es la definición de Retorno sobre activos?



El rendimiento de los activos indica cuál rentables son los activos de una empresa para generar ingresos. Se calcula dividiendo la utilidad neta por el promedio de los activos totales.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Retorno sobre activos de compañías en Sector Health Care en NASDAQ en comparadas con Edesa Biotech

¿Qué hace Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Empresas con retorno sobre activos similar a Edesa Biotech